OS Therapies (OSTX) Net Cash Flow (2023 - 2026)
OS Therapies' (OSTX) quarterly Net Cash Flow came in at $611260.0 in Q1 2026, up 123.85% YoY from $273062.1 in Q1 2025, and up 138.98% on a QoQ basis from -$1.6 million in Q4 2025.
OS Therapies (OSTX) Net Cash Flow (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Net Cash Flow data on file, last reported at $611260.0 in Q1 2026.
- Quarterly Net Cash Flow rose 123.85% year-over-year to $611260.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 171.46% YoY) and the FY2025 annual result came in at -$5.2 million, down 195.1% from the prior year.
- Net Cash Flow rose to $611260.0 in Q1 2026, from -$1.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $3.7 million in Q4 2024 to a low of -$2.6 million in Q1 2025.
- A 4-year average of $57552.8 and a median of -$5306.0 in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow soared 15933.78% — and 2025, when it tumbled 4283.77%.
- Tracing OSTX's Net Cash Flow over 4 years: stood at $22923.0 in 2023, then soared by 15933.78% to $3.7 million in 2024, then slumped by 142.67% to -$1.6 million in 2025, then surged by 138.98% to $611260.0 in 2026.
- The last three Net Cash Flow figures came in at $611260.0 (Q1 2026), -$1.6 million (Q4 2025), and -$925387.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | -679,645.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 611,260.00 |
| Mar 31, 2026 | 611,260.00 |
| Dec 31, 2025 | -1.57 Mn |
| Dec 31, 2025 | -1.57 Mn |
| Sep 30, 2025 | -925,387.00 |
| Sep 30, 2025 | -925,387.00 |
| Jun 30, 2025 | -168,994.00 |
| Jun 30, 2025 | -168,994.00 |
| Mar 31, 2025 | -2.56 Mn |
| Mar 31, 2025 | -2.56 Mn |
| Dec 31, 2024 | 3.68 Mn |
| Dec 31, 2024 | 3.68 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Sep 30, 2024 | 1.76 Mn |
| Jun 30, 2024 | -5,306.00 |
| Jun 30, 2024 | -5,306.00 |
| Mar 31, 2024 | 61,249.00 |
| Mar 31, 2024 | 61,249.00 |
| Dec 31, 2023 | 22,923.00 |
| Dec 31, 2023 | 22,923.00 |